Ellis S R, Hulton S A, McKiernan P J, de Ville de Goyet J, Kelly D A
The Liver Unit, Birmingham Children's Hospital NHS Trust, Birmingham, UK.
Nephrol Dial Transplant. 2001 Feb;16(2):348-54. doi: 10.1093/ndt/16.2.348.
Primary hyperoxaluria type 1 (PH1) is a rare condition in which deficiency of the liver enzyme alanine:glyoxylate aminotransferase leads to renal failure and systemic oxalosis. Combined liver-kidney transplantation (LKT) is recommended for end-stage renal failure (ESRF) in adults, but management of infants and young children is controversial. We retrospectively reviewed six children who underwent LKT for PH1.
The median age at diagnosis was 1.8 years (range 3 weeks to 7 years). Two children presented with severe infantile oxalosis at 3 and 9 weeks, five patients had ESRF with nephrocalcinosis and systemic oxalosis, (median duration of dialysis 1.3 years), and one had progressive chronic renal failure. Four children underwent combined LKT, one child staged liver then kidney, and one infant had an isolated liver transplant. The median age at transplantation was 8.9 years (range 1.7-15 years).
Overall patient survival was four out of six. The two infants with PH1 and severe systemic oxalosis died (2 and 3 weeks post-transplant) due to cardiovascular oxalosis and sepsis. The other four children are well at median follow-up of 10 months (range 6 months to 7.4 years). No child developed hepatic rejection and all have normal liver function. Renal rejection occurred in three patients. Despite maximal medical management, oxalate deposits recurred in all renal grafts, contributing to graft loss in one (one of the infants who died), and significant dysfunction requiring haemodialysis post-transplant for 6 months.
LKT is effective therapy for primary oxalosis with ESRF but has a high morbidity and mortality rate in children who present in infancy with nephrocalcinosis and systemic oxalosis. We feel that earlier LKT, or pre-emptive liver transplantation, may be a better therapeutic strategy to improve the outlook for these patients.
1型原发性高草酸尿症(PH1)是一种罕见疾病,肝脏酶丙氨酸:乙醛酸转氨酶缺乏会导致肾衰竭和全身草酸沉积。对于成年终末期肾衰竭(ESRF)患者,建议进行肝肾联合移植(LKT),但婴幼儿的治疗存在争议。我们回顾性分析了6例接受LKT治疗PH1的儿童患者。
诊断时的中位年龄为1.8岁(范围3周龄至7岁)。2例患儿分别于3周龄和9周龄时出现严重的婴儿型草酸沉积症,5例患者患有ESRF并伴有肾钙质沉着症和全身草酸沉积(透析中位时间为1.3年),1例患有进行性慢性肾衰竭。4例儿童接受了LKT,1例儿童先进行肝脏移植,然后进行肾脏移植,1例婴儿接受了单纯肝脏移植。移植时的中位年龄为8.9岁(范围1.7 - 15岁)。
6例患者中总体有4例存活。2例患有PH1和严重全身草酸沉积症的婴儿在移植后2周和3周死亡,死因分别为心血管草酸沉积症和败血症。其他4例儿童在中位随访10个月(范围6个月至7.四年)时情况良好。无患儿发生肝排斥反应,且所有患儿肝功能均正常。3例患者发生肾排斥反应。尽管采取了最大程度的药物治疗,所有肾移植受者均复发草酸沉积,其中1例(死亡婴儿之一)导致移植肾失功,1例移植后出现严重功能障碍,需要进行6个月的血液透析。
LKT是治疗原发性草酸沉积症合并ESRF的有效方法,但对于婴儿期出现肾钙质沉着症和全身草酸沉积症的儿童,其发病率和死亡率较高。我们认为,早期进行LKT或预防性肝脏移植可能是改善这些患者预后的更好治疗策略。